

***H. pylori* Stool Antigen Testing**

Following the 2017 ACG Guidelines for *H. pylori* diagnosis

Over half the global population has been infected with *H. pylori*, the most widespread bacterial infection in the world (1, 2). Even in developed countries, where overall infection levels have been declining, physicians encounter high prevalence rates, which are even greater among immigrant and economically disadvantaged patients. Serology testing is a common way to detect *H. pylori* antibodies, but as patients can remain seropositive for many years following an infection, are not useful in determining current disease. How then can diagnosis and treatment decisions be made?

***H. pylori* Pathology**

H. pylori is typically acquired in childhood. If left untreated, it persists and remains transmissible for the lifetime of the patient (3, 4). Prevalence rates increase with age, but lower rates of *H. pylori* infection in children reflects recent improvements in control and transmission in the young. Transmission between family members is frequent (1, 4), with grandparents a common, unsuspecting source of infection (5).

Symptoms of *H. pylori* infection initially include pain in the stomach or upper abdomen. The bacteria penetrate the protective gastric mucous to trigger irritation, neutrophil invasion, and inflammation of the gastric surface, leading to gastritis (6). It is not known what portion of exposed individuals escape or suppress active inflammation, but for those with persistent colonization, gastritis and acid secretion set the stage for further complications (7).

In 10-20% of infected patients, chronic and active inflammation lead to the subsequent development of peptic ulcers (6). For patients with intact acid secretion, *H. pylori* will be more abundant and tissue inflammation more prominent in the gastric antrum with fewer bacteria and less inflammation in the corpus (6). These patients are more likely to develop antral and duodenal ulcers. Previously, *H. pylori* infection was responsible for 90% of duodenal ulcers and 80% of gastric ulcers (1). Currently, in developed countries, although *H. pylori* infections are decreasing, an increasing portion of peptic ulcer disease is linked to use of non-steroidal anti-inflammatory drugs


(NSAIDs) (1, 8). Patients who are considering long-term NSAID therapy should be tested for *H. pylori* infection, as the combination further increases the risk of ulcer development (9). This changing incidence emphasizes the importance of correct diagnosis of dyspepsia and ulcerations to differentiate disease caused by drugs from disease caused by *H. pylori* infection.

Patients with low acid secretion, notably those taking proton pump inhibitors (PPIs), can develop gastritis throughout the stomach, with ulcers occurring where inflammation is most severe (6). Complications of ulcers are serious, including bleeding, perforation, and strictures. If bleeding ulcers are caused by *H. pylori*, there is a high risk of recurrence; antibiotic therapy to eradicate the bacteria is usually successful and reduces this risk (6). When low acid secretion allows inflammation to remain chronically active, patients can develop metaplasia and, eventually, inflammation-induced gastric cancers. Atrophic gastritis is a precursor to gastric cancer and decreases acid secretion even further (10).

General *H. pylori* infection is associated with a 2-3 fold increased risk of gastric cancer or mucosal associated-lymphoid-type (MALT) lymphoma (1). Stomach cancers were previously a common type of cancer in the United States. In parallel with the decreasing incidence of *H. pylori* infections, stomach cancers have declined and are estimated to be the 15th most common cancer in the USA. Nevertheless, 5-year overall survival rates are only 31% and 10,800 people in the USA and over 700,000 people globally die from stomach cancer annually (1, 9, 11). For the 35% of patients who have metastatic disease, the relative 5-year survival is only 5% (11). Because *H. pylori* colonization is the single biggest risk factor for stomach cancer (1) and because the bacteria are classified as a Class I carcinogen, diagnosis of infection is clinically important.

***H. pylori* Treatment**

The ability to treat and cure *H. pylori* infections with antibiotics has revolutionized clinical care of patients and reversed long-standing disease trends. Improving



what had been a life-long, deteriorating condition, eradication of *H. pylori* decreases inflammation, and if therapy is given before atrophic changes occur, even the risk of cancer can be virtually abolished (10).

There are multiple therapies that can be successful (12). Triple therapy is widely used and consists of a PPI, amoxicillin and clarithromycin for 10-14 days (9). Sequential therapy utilizes amoxicillin plus a PPI for the first 5 days then moves to a triple therapy of a PPI and two antibiotics, such as clarithromycin and tinidazole (9). Eradication of *H. pylori* is becoming more difficult due to increasing resistance of *H. pylori* strains to clarithromycin, making these treatments less effective (13). Recent studies show that clarithromycin resistance is 32% in the USA and 50% in Japan (4), while metronidazole resistance in Africa is over 90% (9). As a result, the AGC 2017 Guidelines suggest using treatment regimens without clarithromycin if local resistance rates exceed 20% (3). This resistance has led to development of a quadruple therapy that uses a PPI, a bismuth product and antibiotics such as metronidazole and tetracycline for 10-14 days (9). However, for *H. pylori*-infected patients who are pregnant, bismuth, tetracycline and fluoroquinolones are potential teratogens and should be avoided (9).

Because of antibiotic resistance, attempts to eliminate *H. pylori* with these regimens have increasing failure rates and eradication can no longer be assumed. Elimination of the bacteria should be confirmed 4 weeks after the treatment is finished, using a test such as a stool antigen assay, rather than a serology test (antibodies to *H. pylori* are formed within 3 weeks post-infection) (9). Guidelines recommend follow-up testing four weeks post-treatment as this time-frame allows any surviving *H. pylori* to re-grow to detectable levels (3).

***H. pylori* Diagnosis**

Multiple professional gastroenterology groups have endorsed a “Test-Treat-Test” approach that involves first using a non-invasive diagnostic test to determine if a patient with dyspepsia is infected with *H. pylori*, treatment if infection is present, then follow-up testing to confirm removal of the bacteria (3, 7, 12). For patients this prevents the expense, inconvenience, and discomfort of endoscopy. For physicians, diagnosis can be rapid, and therapy initiated with confidence.

H. pylori infections and associated symptoms and inflammation can wax and wane. Patients typically seek medical care for troubling symptoms during a period of active inflammation. If *H. pylori* diagnostic


testing is positive, they should receive eradication treatment to prevent worsening disease and to potentially reverse and heal their current lesions. The AGC 2017 Guidelines indicate that if a physician plans to test a patient for *H. pylori* then the patient should be treated if positive (3). The fundamental decision then, is not whether to treat, but rather what test should be used to diagnose an active infection. Tests for *H. pylori* fall into two main categories: invasive and non-invasive. Invasive tests utilize endoscopy as the means to observe lesions and obtain biopsies for histology, rapid urease testing, polymerase chain reaction (PCR) assays and culture. Non-invasive tests include serology for *H. pylori*-directed antibodies, urea breath tests, and stool antigen tests.

Endoscopy

For the physician, endoscopy is the only method that allows visualization of the actual gastric or duodenal lesions and their location within the stomach. Sites where inflammation is found are associated with increased risks for gastritis, ulcers, or cancer (6). This knowledge is invaluable for late-stage diagnosis. However, for *H. pylori* detection, other types of tests are less expensive and more convenient for both patient and physician, and do not require highly trained personnel. The risks of anesthesia and endoscopy are a particular problem for pregnant or pediatric patients and should be avoided when possible (9).

When simpler front-line non-invasive tests indicate that endoscopy would be beneficial, additional information can be gained during the endoscopic exam (9). In addition, patients that have alarm symptoms (vomiting, GI bleeding, weight loss) should be evaluated immediately and directly by endoscopy (3, 9). Biopsies are an important part of the procedure and must be taken from at least 3 sites within the stomach and duodenum because inflamed regions are often patchy (9).

Biopsy samples are used for histology to establish the presence of bacteria in inflamed areas and for rapid urease testing to establish the viability of the bacteria. Cultures, the ultimate confirmation method that the bacteria are alive, can also be made from biopsy specimens if antibiotic sensitivity testing is needed, but require special growth media and take 5-7 days to grow. However, antibiotic treatment within four weeks of the endoscopy (or stool antigen tests) may suppress bacteria to below detectable levels without full eradication. Thus, antibiotics must be avoided prior to these tests to prevent false negative results (9).



Molecular detection of *H. pylori* DNA is also feasible from biopsy samples. PCR is quite sensitive but cannot determine if the bacterial source of the DNA is viable (9). Rapid urease tests are based on the activity of the urease enzyme of viable *H. pylori* which will convert urea to ammonia. This is how the bacteria naturally moderate the pH of their locale in the acidic environment of the stomach (6). The combination of endoscopy with histology and rapid urease testing have been used as a reference method for *H. pylori* diagnosis in the development of more rapid, simpler, non-invasive stool antigen tests (see below).

Serology

Antibody testing detects IgG antibodies specific to *H. pylori* in serum, whole blood, or urine. These antibodies develop about 3 weeks after infection but can persist for years after an infection has resolved (6). For the patient, samples are easy to obtain during an office visit and the test results can be obtained quickly.

However, antibody tests provide no clinical information on whether an *H. pylori* infection is active and the source of current symptoms and thus deserves therapy, or is inactive, with symptoms deriving from another cause that needs investigation.

Although serology is a common test for *H. pylori*, it not accurate for current infections and is of limited utility in areas with a high rate of prevalence, or as a test-of-cure (3, 6). Many labs no longer offer serology testing because of this drawback.

Urea Breath Tests

For the assay, the patient drinks ¹³C- or ¹⁴C-labeled urea. The procedure is not recommended for children and pregnant women. If *H. pylori* is present in the stomach, urease produced by the organism breaks down urea from the gastric juices into ammonia and CO₂. The CO₂ travels to the lungs and is exhaled. A scintillation cocktail is used to determine the amount of ¹⁴CO₂ released. Mass spectrometry is used for ¹³CO₂. The test performance of UBTs is comparable to performance observed with invasive procedures. Patients should refrain from the use of proton pump inhibitors, antibiotics, and bismuth-containing medications for several weeks prior to the use of UBTs (9).

Stool Antigen Testing

Stool antigen testing is a widely accepted non-invasive and simple option for patient and physician, making it a good frontline tool for diagnosis. The test is specifically designed to identify current infection by detecting antigen(s) that are produced by live *H. pylori* bacteria and shed into the stool (2). Additionally, stool antigen testing reflects infection from throughout the stomach and duodenum, an advantage over endoscopy (9). Stool antigen tests are simple to perform in small labs or resource-poor regions, involve a sample that can be collected non-invasively, (a particular advantage in children and other sensitive populations), and are economical for patient and clinic. Because of these characteristics, stool tests are a good first choice for initial detection of *H. pylori*, for confirming success of treatment or eradication therapy, as well as for patients that may need frequent monitoring such as *H. pylori*-infected pregnant women.

Flexible specimen transport conditions are an important feature of the tests because specimens are usually collected by the patient, who is not at the point of testing and must manage sample storage and handling until it reaches the testing site.


Recently TECHLAB, Inc. has released two new FDA-cleared stool antigen enzyme-based immunoassays, the *H. PYLORI CHEK*[™] 96-well format test and the rapid membrane-based *H. PYLORI QUIK CHEK*[™] test. The *H. PYLORI QUIK CHEK*[™] test detects

H. pylori in 30 minutes, while the *H. PYLORI CHEK*[™] test can be performed with or without automation in one hour. The *H. PYLORI CHEK*[™] and *H. PYLORI QUIK CHEK*[™] tests exhibit excellent sensitivity and specificity (Table 1) and offer flexible specimen transport conditions including room temperature storage of specimens for 96 hours and the use of C&S and Cary Blair transport media to simplify sample collection for patients and physician. The strength of performance of these tests was verified as both an initial diagnostic and a test of cure against histology and urease testing performed on clinical biopsies collected during endoscopy.

Table 1. Clinical Performance of *H. pylori* Stool Antigen Tests for Initial Diagnosis

	<i>H. PYLORI CHEK</i> [™]	<i>H. PYLORI QUIK CHEK</i> [™]
Sensitivity	100% (89.3%-98.9%)	97% (84.7%-99.5%)
Specificity	96.1% (89.2%-98.7%)	100% (95.9%-100%)

95% Confidence Intervals are shown in parentheses.



Proton pump inhibitors (PPIs), antibiotics or bismuth compounds are known to inhibit *H. pylori* and may cause false negative results if the patient has used any of these within 14 days of fecal sample collection. If a patient taking any of these medications has a negative test result, the medication(s) should be stopped, and a new fecal sample collected after 14 days. However, for the *H. PYLORI CHEK™* and *H. PYLORI QUIK CHEK™* tests, if a patient taking these medications does show a positive *H. pylori* test result, the positive result is considered accurate.

Summary

The 2017 ACG Clinical Guideline strongly emphasize a “Test-Treat-Test” approach. This approach is critical because if treatment does not work, the patient will continue to be infected with *H. pylori* and continue to be at-risk for *H. pylori*-related disease such as peptic ulcer disease and gastric cancer.

The guidelines enforce the following points:

- *H. pylori* testing should be performed for all patients with active peptic ulcer disease, mucosa-associated lymphoma or early gastric cancer.
- All tested patients who are positive for active *H. pylori* infection should be offered treatment.
- Due to high rates of antibiotic resistance, patients should be re-tested after treatment to confirm eradication with a method that identifies active disease.
- Testing methods which detect active disease, such as stool antigen testing, are preferred.

References

1. Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. 2017. Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models. *Disease Models & Mechanisms* 10:89-104.doi: 10.1242/dmm.027649.
2. Polk DB, Peek RM. 2010. Helicobacter pylori: gastric cancer and beyond. *Nature Reviews Cancer* 10:403-414.doi: 10.1038/nrc2857.
3. Chey WD, Leontiadis GI, Howden CW, Moss SF. 2017. ACG Clinical Guidelines: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol* 112:212-238.doi: 10.1038.
4. El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe S, Elfant A, Haas T, Hapke RJ, Graham DY. 2018. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. *Clinical Gastroenterology and Hepatology* 16:992-1002. e1006.10.1016/j.cgh.2018.03.013.
5. Urita Y, Watanabe T, Kawagoe N, Takemoto I, Tanaka H, Kijima S, Kido H, Maeda T, Sugasawa Y, Miyazaki T, Honda Y, Nakanishi K, Shimada N, Nakajima H, Sugimoto M, Urita C. 2013. Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town. *Journal of Paediatrics and Child Health* 49:394-398.doi:10.1111/jpc.12191.
6. Kusters JG, van Vliet AHM, Kuipers EJ. 2006. Pathogenesis of Helicobacter pylori Infection. *Clinical Microbiology Reviews* 19:449-490.doi: 10.1128/cmr.00054-05.
7. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. 2012. Management of Helicobacter pylori infection-- the Maastricht IV/ Florence Consensus Report. *Gut* 61:646-664.doi: 10.1136/gutjnl-2012-302084.
8. Musumba C, Jorgensen A, Sutton L, Eker D, Moorcroft J, Hopkins M, Pritchard DM, Pirmohamed M. 2012. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. *Alimentary Pharmacology & Therapeutics* 36:48-56.doi:10.1111/j.1365-2036.2012.05118.x.
9. Testerman TL, Morris J. 2014. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. *World J Gastroenterol* 20:12781-12808.doi: 10.3748/wjg.v20.i36.12781.
10. Graham DY. 2015. Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. *Gastroenterology* 148:719-731.e713. doi: 10.1053/j.gastro.2015.01.040.
11. NCI. Cancer Stat Facts: Stomach Cancer, on NIH National Cancer Institute Surveillance, Epidemiology, and End Results Program. <https://seer.cancer.gov/statfacts/html/stomach.html>. Accessed August 17, 2018.
12. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, Van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BCY, Krabshuis J, Mair AL. 2010. World Gastroenterology Organisation Global Guidelines: Helicobacter pylori in developing countries. PMID: 21961099.
13. Park JY, Dunbar KB, Mitui M, Arnold CA, Lam-Himlin DM, Valasek MA, Thung I, Okwara C, Coss E, Cryer B, Doern CD. 2016. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. *Digestive Diseases and Sciences* 61:2373-2380.doi: 10.1007/s10620-016-4091-8.

